Back to top
more

Vanguard Health Care ETF: (VHT)

(Delayed Data from NYSE) As of Feb 20, 2026 04:00 PM ET

$290.48 USD

290.48
208,848

-0.39 (-0.13%)

Volume: 208,848

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

1 - Strong Buy of 5 1        

After-Market: $289.79 -0.69 (-0.24 %) 7:58 PM ET

Zacks News

Sweta Jaiswal, FRM headshot

Here's Why Healthcare ETFs Are Rallying Post Elections

Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

Sweta Killa headshot

UnitedHealth Q3 Solid Result Put Healthcare ETFs in Focus

UnitedHealth reported better-than-expected third-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues. It also lifted its full year outlook.

Sweta Jaiswal, FRM headshot

J&J Pauses Coronavirus Vaccine Trial: ETFs That May Take a Hit

Johnson & Johnson's pausing of dosing in all clinical studies on its coronavirus vaccine candidate has increased uncertainty surrounding the coronavirus vaccine development.

Sweta Killa headshot

JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus

Despite solid results and an upbeat view, shares of JNJ dropped as the company halted its final-phase of clinical trials for its COVID-19 vaccine candidate.